Cancer Gains

When late US President Richard Nixon launched his “War on Cancer” in 1971, the ambition was audacious: find a cure within a decade. More than half a century later, cancer still claims nearly 10 million lives globally every year. Yet the world is inching toward a quieter, less headline-grabbing victory. It is doing so not through a singular cure, but through steady advances in prevention, diagnosis, and treatment that are transforming cancer into a disease many people can survive ~ or avoid altogether.

The clearest evidence of this transformation is in age-adjusted death rates. In the United States, those rates have fallen by roughly a third since the early 1990s, translating to an estimated 3 to 4 million fewer deaths. Similar declines have been recorded in over 140 countries. Adjusting for rising life expectancy, this means people today are significantly less likely to die of cancer at any given age than their parents were. Survival rates have risen sharply as well. In highincome countries, five-year relative survival now exceeds 85 per cent for many common cancers.

Advertisement

These gains have been driven by earlier detection and by more precise, less toxic treatment regimes. Immunotherapy, in particular, has rewritten the rules. Drugs like pembrolizumab and dostarlimab have extended survival in lung and colorectal cancers, while CAR-T cell therapies are now showing promise in solid tumours. A study presented at this year’s ASCO meeting in Chicago found that neoadjuvant immunotherapy increased event-free survival in melanoma patients from 57 per cent to 84 per cent in just 12 months. Many cancers are now being treated as chronic illnesses rather than death sentences, allowing patients to resume normal lives with manageable treatment plans and on-going monitoring, often for years.

Preventive measures are equally crucial. Antismoking campaigns in the West have averted millions of cancer deaths since the 1970s. The HPV vaccine, first introduced less than two decades ago, has already slashed cervical cancer incidence by up to 90 per cent among young women in countries with high vaccination rates. Screening for colorectal, breast, and prostate cancers has grown more effective and more widespread. Yet progress remains uneven. In many low-and middle-income countries, basic diagnostic tools, vaccines, and standard therapies remain inaccessible. Even in wealthier nations, significant disparities exist. People in rural areas or low-income communities, as well as some racial and ethnic minorities, continue to face poorer outcomes despite medical advances.

The war on cancer was never going to be won by shock-and-awe tactics. The real battle has been a war of attrition ~ slow, scientific, and cumulative. While the disease remains one of the leading causes of death worldwide, the momentum has shifted. Breakthroughs in mRNA-based vaccines and precision oncology suggest that the coming decades may see even deeper inroads. The world has not cured cancer. But it has made it far less deadly. That, quietly and steadily, is what winning looks like.